Name: Yarmela Pavlovic
New title: Chief regulatory officer, Medtronic
Previous title: Vice president global regulatory affairs, strategy and policy, Medtronic
Medtronic has appointed Yarmela Pavlovic as its chief regulatory officer. Pavlovic will collaborate with leaders at Medtronic operating units to guide the overall direction of regulatory affairs at the company.
Pavlovic joined Medtronic as vice president of regulatory strategy in 2021 and took up the post of vice president of global regulatory affairs, strategy and policy one year ago.
“Having Yarmela as our chief regulatory officer allows for an even stronger focus on regulatory affairs at Medtronic,” a Medtronic spokesperson wrote in an email.
The latest change gives Pavlovic a new title, but her role will stay the same. Pavlovic, who was a partner at the law firm Manatt, Phelps & Phillips before joining Medtronic, is not on Medtronic’s executive leadership team but will “meet with that team and the board as needed on strategic regulatory topics,” the spokesperson said.
Pavlovic will still report to Laura Mauri, Medtronic’s chief scientific and medical officer.
The changes, which Mauri disclosed in a Linkedin post, come as Medtronic works toward regulatory goals such as the U.S. approval of its next-generation continuous glucose monitor sensor Simplera.